Bladder cancer is one of the most common malignancies in the world. Cisplatin is one of the most potent and widely used anticancer drugs and has been employed in several malignancies. Cisplatin-based combination chemotherapies have become important adjuvant therapies for bladder cancer patients. Cisplatin-based treatment often results in the development of chemoresistance, leading to therapeutic failure and limiting its application and effectiveness in bladder cancer. To develop improved and more effective cancer therapy, research has been conducted to elucidate the underlying mechanism of cisplatin resistance. Epigenetic modifications have been demonstrated involved in drug resistance to chemotherapy, and epigenetic biomarkers, such as urine tumor DNA methylation assay, have been applied in patients screening or monitoring. Here, we provide a systematic description of epigenetic mechanisms, including DNA methylation, noncoding RNA regulation, m6A modification and posttranslational modifications, related to cisplatin resistance in bladder cancer.

膀胱癌是世界上最常见的恶性肿瘤之一。顺铂是最有效和最广泛使用的抗癌药物之一，已用于多种恶性肿瘤。基于顺铂的联合化疗已成为膀胱癌患者的重要辅助疗法。基于顺铂的治疗通常会导致化学耐药性的发展，从而导致治疗失败并限制其在膀胱癌中的应用和有效性。为了开发改进的和更有效的癌症疗法，已经进行了研究以阐明顺铂抗性的潜在机制。表观遗传修饰已被证明与化疗耐药有关，表观遗传生物标志物，如尿液肿瘤 DNA 甲基化测定，已应用于患者筛查或监测。这里，